Drug Discovery World

FEBRUARY 23, 2024

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). The FDA review was conducted under Project Orbis, which provides a framework for concurrent submission and review of oncology drugs among international partners.

Therapies 130

Therapies FDA Trials Treatment 130

Drug Discovery World

MARCH 2, 2023

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in targeted treatments for cancer and asked what advances the future might bring. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

DECEMBER 4, 2023

The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. Elenagen also reduced systemic chronic inflammation in the organism, which plays a detrimental role in many diseases, including cancer.

DNA 148

DNA Therapies Packaging Vaccine 148

Drug Discovery World

APRIL 11, 2023

Owing to the complexity of severe asthma, many patients have unclear or multiple drivers of airway inflammation resulting in some patients not responding to the current standard of treatment, and being at increased risk of asthma attacks, hospitalisations, and a poor quality of life 3,4,5,6. to 0.53; P<0.001).3 2005;172:149-160.

Treatment 246

Treatment Clinical Trials Trials Science 246

Drug Discovery World

DECEMBER 13, 2022

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. . Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. .

Treatment 130

Treatment Clinical Trials Laboratories Therapies 130

Drug Discovery World

JULY 19, 2023

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.

Disease 130

Disease Trials Clinical Trials Therapies 130

Drug Discovery World

OCTOBER 31, 2023

Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. These parameters aim to measure the progression of disease over time by looking at the functional or observable change in a patient.

Drug Development 148

Drug Development Disease Drugs Clinical Trials 148

Drug Discovery World

DECEMBER 1, 2023

The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and using CRISPR gene editing to ‘shred’ tumours. Can a plant-based discovery pave the way for new drug treatments?

Therapies 130

Therapies Drugs Disease International 130

DrugBank

JUNE 13, 2024

These innovative technologies are changing how medications reach their targets within the body, leading to more effective treatments with fewer side effects.   Take cancer treatment, for example. Implantable insulin pumps equipped with continuous glucose monitoring (CGM) sensors can update old diabetes treatment options.

Therapies 76

Therapies Drugs DNA Engineering 76

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel Phase II trial incorporating Hu14.18 and three-year event-free (EFS) of 73.7%.

Licensing 246

Licensing Licensing Hospitals Therapies 246

Drug Discovery World

JULY 13, 2022

The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC). . Many people with sickle cell disease experience recurrent painful crises which can result in hospital admission.

Treatment 130

Treatment Hospitals International Disease 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute.

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics International Clinical Trials Drugs 130

Drug Discovery World

AUGUST 26, 2022

A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments.

International 130

International Drugs Clinical Trials Treatment 130

Drug Discovery World

MAY 30, 2024

Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”

Small Molecule 148

Small Molecule Treatment International Production 148

Drug Discovery World

JANUARY 5, 2024

The top stories: China’s NMPA okays maribavir for post-transplant cytomegalovirus Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease.

International 130

International Drugs FDA Regulations 130

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 48

Disease Pharmaceuticals Therapies Clinical Trials 48

Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Clinical Trials 130

Clinical Trials Drugs Trials Therapies 130

Drug Discovery World

JUNE 28, 2023

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). Acute TTP events have a mortality rate of >90%, if left untreated.

Trials 130

Trials Clinical Trials Therapies Drugs 130

Drug Discovery World

SEPTEMBER 16, 2022

A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. . First biologic therapy for young children with severe eczema . Trial sheds light on combined treatment for colorectal cancer .

FDA Approval 130

FDA Approval Drugs FDA Clinical Trials 130

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We

Research 130

Research Clinical Trials Therapies Clinical Development 130

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

Drug Discovery World

JUNE 6, 2023

A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Studies have shown the drug can become ineffective over time as tumours develop resistance to treatment.

Drugs 130

Drugs Treatment Clinical Trials Trials 130

Drug Discovery World

AUGUST 30, 2022

A new study has found that the antiviral tecovirimat (TPOXX) appears to be safe and effective for the treatment of monkeypox symptoms and skin lesions. TPOXX is an FDA-approved antiviral drug for the treatment of smallpox. Context and treatment. All patients completed the tecovirimat therapy and tolerated their treatment well.

Therapies 130

Therapies FDA Approval Vaccine Treatment 130

Vial

DECEMBER 11, 2023

Pathophysiological evidence links HCV infections to the risk of liver diseases such as hepatocellular carcinoma (HCC) and liver cirrhosis. Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

OCTOBER 24, 2023

MP : We currently develop CRISPR based molecular tools for clients creating new therapies for the treatment of various diseases, but we also work in diagnostics and agriculture. As an example, we work with Spanish company Integra Therapeutics, combining their technology with ours to develop a therapeutic treatment approach.

Science 264

Science Molecular Biology Government Regulations 264

Drug Discovery World

MARCH 21, 2023

Held in the US March every year, the aim of National Colorectal Cancer Awareness Month is to improve awareness of the disease in the hope that more cases can be treated in time. Improved diagnostics Diagnostics and screening are essential to the early treatment of colorectal cancer.

RNA 130

RNA Clinical Trials Drugs Therapies 130

Drug Discovery World

JANUARY 27, 2023

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer. The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Engineering 130

Engineering Drugs Therapies International 130

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

The Pharma Data

MAY 5, 2022

Novartis today announced the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GvHD who have inadequate response to corticosteroids or other systemic therapies.

Treatment 52

Treatment Disease Therapies Clinical Trials 52

Drug Discovery World

SEPTEMBER 27, 2023

The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable. Approximately 24,000 people live with MM in the UK, and over 5,000 people in England and 260 in Wales are diagnosed annually.

Regulations 130

Regulations Licensing Licensing Therapies 130

Drug Discovery World

MARCH 31, 2023

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer. As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.

Vaccine 130

Vaccine Drugs Clinical Trials International 130

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

Drug Discovery World

SEPTEMBER 7, 2023

Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. 4 Recent regulatory initiatives in the United States and Europe have aimed to increase the study of novel anti-cancer therapies in children.

Clinical Trials 148

Clinical Trials Trials Drugs DNA 148

FDA Law Blog: Drug Discovery

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” It finalized a draft guidance published in 2022.

Therapies 59

Therapies FDA Production Regulations 59

The Pharma Data

JULY 15, 2021

Challenge to Support an Innovative Solution That Addresses Disconnect in Perception of Psoriatic Disease Severity and Undertreatment Documented in Multinational UPLIFT Survey UPLIFT Data Presented at WPPAC 2021 Report Substantial Disease Burden for People Living With Psoriasis and Psoriatic Arthritis.

International 52

International Disease Treatment Science 52